Open AccessEfficacy and safety of antifibrinolytic agents in spinal surgery
Author(s) -
Yuan Lu,
Yan Zeng,
Zhongqiang Chen,
Xinling Zhang,
Shuo Mai,
Peng Song,
Liyuan Tao
Publication year - 2019
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000000108
Subject(s) - medicine , tranexamic acid , aprotinin , antifibrinolytic , randomized controlled trial , placebo , perioperative , cochrane library , anesthesia , blood loss , aminocaproic acid , meta analysis , blood transfusion , surgery , alternative medicine , pathology
Significant blood loss is still one of the most frequent complications in spinal surgery, which often necessitates blood transfusion. Massive perioperative blood loss and blood transfusion can create additional risks. Aprotinin, tranexamic acid (TXA), and epsilon-aminocaproic acid (EACA) are antifibrinolytics currently offered as prophylactic agents to reduce surgery-associated blood loss. The aim of this study was to evaluate the efficacy and safety of aprotinin, EACA, and low/high doses of TXA in spinal surgery, and assess the use of which agent is the most optimal intervention using the network meta-analysis (NMA) method.